Business
MCAP: Q1 2026 delivered double-digit revenue and profit growth, driven by strong segment performance
MCAP: Q1 2026 delivered double-digit revenue and profit growth, driven by strong segment performance
About this update from Medcap Ab
Q1 2026 saw 13% revenue growth and 30% adjusted EBITA growth, with strong margins led by Assistive Tech and MedTech. Specialty Pharma improved but remains a focus for margin enhancement, while a robust balance sheet supports further acquisitions.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.